Related Experiment Videos
Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study
B Haghighi1, B R Smoller, P E LeBoit
1Department of Pathology, Stanford University Medical Center, California 94305-5302, USA.
Abstract:
Pagetoid reticulosis (PR), also known as Woringer-Kolopp disease, is a form of cutaneous T-cell lymphoma that demonstrates striking epidermotropism on histologic examination. We present the histologic, immunologic, and molecular findings for seven patients who had PR. The patients ranged in age from 33 to 67 years. All patients presented with one or several thick plaques involving the distal extremities except for one patient, who presented with a tongue lesion. Immunohistochemical staining of the atypical lymphoid cells demonstrated a T-cell phenotype in all cases. In one of four frozen cases, the neoplastic cells were of T-helper cell phenotype (CD4 positive). Four of seven cases demonstrated a T-cytotoxic/suppressor cell phenotype (CD8 positive). The T-cell subset for the remaining two cases could not be determined. CD30 positivity and a high growth fraction as indicated by staining with Ki-67 were seen in three of seven and three of four cases, respectively. Genotypic analysis performed on three of our cases revealed T-cell receptor (gamma and/or beta) rearrangement, indicating a clonal proliferation. The clinical follow-up ranged from 15 months to 13 years. Four of seven patients are alive and free of disease after treatment with excision or local irradiation. One patient relapsed twice after treatment with radiation and photochemotherapy with 8-methoxypsoralen and UVA and was then lost to follow-up. The lesions of another patient resolved spontaneously but recurred at the same and in an additional site 5 years later. One patient recurred after electron beam therapy. The recurrent lesion improved with radiation therapy and local wound care but never resolved completely. The patient died of unrelated causes. Our findings suggest that PR is a distinct clinicopathologic entity, separate from unilesional mycosis fungoides, demonstrating a slow disease course. The disease is a clonal cutaneous T-cell lymphoma with relatively consistent clinical and histopathologic findings but a heterogeneous immunophenotypic profile.
Insights
Pagetoid reticulosis (PR), a rare T-cell lymphoma, presents with skin plaques and shows epidermotropism. This study highlights its distinct clinicopathologic features and clonal nature, suggesting a slow disease course.
Area of Science:
- Dermatology
- Oncology
- Hematology
Background:
- Pagetoid reticulosis (PR), or Woringer-Kolopp disease, is a T-cell lymphoma characterized by epidermotropism.
- Understanding its distinct clinicopathologic, immunologic, and molecular features is crucial for diagnosis and management.
Purpose of the Study:
- To present the histologic, immunologic, and molecular findings in seven patients diagnosed with Pagetoid reticulosis.
- To characterize the clinical presentation, disease course, and treatment outcomes of PR.
Main Methods:
- Histologic examination with a focus on epidermotropism.
- Immunohistochemical staining to determine T-cell phenotype (CD4, CD8), CD30 expression, and proliferation index (Ki-67).
- Genotypic analysis of T-cell receptor rearrangement to assess clonality.
Main Results:
- Seven patients (33-67 years) presented with thick plaques on extremities or a tongue lesion.
- Immunohistochemistry revealed a T-cell phenotype in all cases, with CD4 or CD8 positivity in most.
- Genotypic analysis confirmed clonal proliferation in three cases; clinical follow-up showed variable outcomes, including spontaneous resolution and recurrence.
Conclusions:
- Pagetoid reticulosis is a distinct clinicopathologic entity, separate from unilesional mycosis fungoides.
- PR is a clonal cutaneous T-cell lymphoma with consistent clinicopathologic findings but a heterogeneous immunophenotypic profile.
- The disease course is generally slow, with varied responses to treatments like excision, irradiation, and photochemotherapy.